Updated June 6th, 2020 at 20:52 IST
Maharashtra sees 2739 new COVID-19 cases with 120 deaths; recovery rate stands at 45.6%
Maharashtra's COVID tally rose to 82,968 after 2739 people tested positive for Coronavirus on June 6, Saturday. There are 42,600 active cases at present
Advertisement
Maharashtra's COVID-19 tally rose to 82,968 after 2,739 people tested positive for Coronavirus on June 6, Saturday. There are 42,600 active cases at present. The number of recovered cases in Maharashtra soared to 37,390 after 2234 COVID-19 patients were discharged in the day.
There were 120 COVID-related deaths reported in the state in the day. Mumbai-58, Thane-10, Navi Mumbai-6, Ulhasnagar-6,
Mira-Bhayandar-5, Vasai-Virar-1, Bhivandi-3, Palghar-1, Nashik-5, Malegaon-2 , Pune-10, Satara-5, Solapur-2, Akola -2, Amaravati-2 , Aurangabad -2.
The recovery and fatality rate pertaining to COVID-19 in the state stands at 45.6% and 3.57% respectively. While, 5,46,566 people are in-home quarantine, 29,098 people are in institutional quarantine currently.
READ: Maharashtra CM meets NCP supremo Sharad Pawar after visiting Cyclone-hit Raigad
READ: Negligence in treating COVID-19 cases a serious issue: Maharashtra Dy CM Ajit Pawar
Maharashtra To Procure 10,000 Vials Of Remdesivir For Treating COVID-19 Patients
The Maharashtra government will procure 10,000 vials of anti-viral drug Remdesivir for treating COVID-19 patients, State Health Minister Rajesh Tope said on Saturday. Remdesivir is the first drug that showed positive results in COVID-19 patients in formal clinical trials. India's Union Health Ministry had on Tuesday approved its emergency use to treat COVID-19 patients.
On Twitter, Rajesh Tope said that the anti-viral drug has generated promising results against other coronavirus-caused diseases like MERS and SARS based on evidence from animal and clinical studies in labs. He cited the World Health Organisation's positive take on the drug in COVID-19 treatment and said it is being made available for poor and needy patients.
Remdesivir was granted emergency use authorization by the US Food and Drug Administration last month and has received approval by Japanese health regulators. In May, the WHO welcomed data from a US government-run clinical trial showing the drug appeared to be effective in reducing recovery times for COVID-19 patients.
READ: Maharashtra sees 'significant' drop in serious crimes during coronavirus lockdown
READ: Maharashtra: NTCA get complaint of illegal tree cutting in Navegaon Nagzira Tiger Reserve
Advertisement
Published June 6th, 2020 at 20:52 IST